Sanjay Nayak, M.B.B.S., Ph.D., is a seasoned healthcare executive with over two decades of experience in ophthalmology, pharmaceuticals, and biotechnology. He earned his M.B.B.S. from a prestigious medical institution in India and later obtained a Ph.D. in Vision Science from the University of Houston, focusing on retinal diseases and drug delivery systems. Early in his career, Dr. Nayak held clinical and research positions at leading institutions, including the Bascom Palmer Eye Institute, where he contributed to groundbreaking studies on age-related macular degeneration and glaucoma therapies. Throughout his professional journey, Dr. Nayak has held pivotal leadership roles at global pharmaceutical giants such as Pfizer and Alcon Laboratories, where he spearheaded the development and commercialization of innovative ocular therapeutics. His notable achievements include leading the successful launch of multiple FDA-approved products for retinal disorders, forging strategic alliances that accelerated pipeline advancement, and authoring over 50 peer-reviewed publications and patents in advanced drug delivery technologies. Recognized as a thought leader, he has presented at international conferences like ARVO and serves on advisory boards for ophthalmic innovation. As Chief Strategy Officer at Ocular Therapeutix, Inc., Dr. Nayak drives the company's long-term vision, overseeing strategic planning, business development, and partnerships to advance its proprietary hydrogel-based platform for sustained drug delivery in ocular diseases. Under his guidance, the company has expanded its clinical pipeline, including DEXTENZA and AXIMRIS, positioning Ocular Therapeutix as a leader in transformative eye care solutions. His strategic acumen continues to propel growth and innovation in addressing unmet needs in ophthalmology.